Relief Therapeutics Aktie
4,15CHF | -0,20CHF | -4,60% |
WKN DE: A3EFB5 / ISIN: CH1251125998
Aktionärsstruktur
Inhaber | in % |
---|---|
Freefloat | 65,83 |
Global Emerging Markets North America, Inc. | 20,58 |
RELIEF THERAPEUTICS Holding SA | 12,98 |
PF – ESG Swiss Equity Fund | 4,34 |
RiverRock Fund V SICAV - Liquid Premium | 3,05 |
Armistice Capital LLC | 2,99 |
Synchrony Market Funds - Optimised SPI | 2,53 |
Hunter Associates Investment Management LLC | 2,14 |
Paolo Galfetti, CFA, MBA | 0,56 |
*Die Summe der Anteile kann 100% überschreiten, da bestimmte Anteilseigner zum Freefloat dazu gerechnet wurden.
Personal
2019 | 2020 | 2021 | 2022 | 2023 | |
---|---|---|---|---|---|
Personal am Ende des Jahres | 0 | 0 | 0 | 0 | 0 |
Umsatz pro Mitarbeiter in Mio. EUR | 0,00 | 0,00 | 0,00 | 0,00 | 0,00 |
Bilanz (in Mio. CHF) - Aktiva
2019 | 2020 | 2021 | 2022 | 2023 | |
---|---|---|---|---|---|
Summe Umlaufvermögen | 0 | 47 | 55 | 23 | 18 |
Summe Anlagevermögen | 20 | 31 | 197 | 166 | 58 |
Summe Aktiva | 20 | 78 | 252 | 189 | 76 |
Bilanz (in Mio. CHF) - Passiva
2019 | 2020 | 2021 | 2022 | 2023 | |
---|---|---|---|---|---|
Summe Fremdkapital | 6 | 11 | 70 | 43 | 24 |
Summe Eigenkapital | 14 | 67 | 182 | 145 | 52 |
Summe Passiva | 20 | 78 | 252 | 189 | 76 |
Adresse
Avenue de Sécheron 15, 1202 Geneva | |
Telefon | +41 (22) 545-11-16 |
Internet | http://www.relieftherapeutics.com |
Management
Andrew J. Einhorn
Chief Financial Officer |
Anthony M. Kim
Senior VP & Head-US Commercial Operations |
Giorgio Reiner
Chief Scientific Officer |
Gregory A. Van Beek
Director |
Melinda Keegan
Chief Human Resources Officer |
Paolo Galfetti
Chief Business Officer |
Peter Egon de Svastich
Director |
Raghuram Selvaraju
Chairman |
Tommy Elzinga
Director |
Vincenzo Gallo
Head-Legal & Compliance |